3 Besides modulating GABAergic receptors in the central nervous system (CNS), GLP-1 agonists delay gastric emptying
Should those oral drugs succeed in Phase 3 trials, they would likely come to the market around 2029, three years behind Lilly, which introduced its small molecule pill Foundayo earlier this year (the Wegovy pill is an oral peptide)
Lixisenatide and beinaglutide Lixisenatide and beinaglutide, including EX-BID as discussed earlier, are classified as short-acting GLP-1RAs based on pharmacokinetic characteristics such as clearance half-life and concentration-time distribution
The first is the obesity epidemic
GLP-1 RAs health benefits: Ongoing studies Beyond weight loss, research suggests GLP-1 RAs could help: Lower the risk of developing or worsening substance disorders Slow down the effects of Parkinsons and Alzheimers Improve heart health and kidney function While these are exciting possibilities, researchers need to conduct more studies before recommending GLP-1s for these conditions
